Geoffrey T. Gibney

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Morganna Freeman-Keller, Young‐Chul Kim, Heather Cronin et al. · Clinical Cancer Research · 2015 · 875 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel, Megan Othus, Yuanbin Chen et al. · New England Journal of Medicine · 2023 · 827 citations · Full text

Medicine, Oncology, Surgery +17

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

Life Sciences, Immunology, Oncology +14

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

Jeffrey S. Weber, Ragini R. Kudchadkar, Bin Yu et al. · Journal of Clinical Oncology · 2013 · 530 citations · Full text

Life Sciences, Immunology, Oncology +15

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Geoffrey T. Gibney, Ragini R. Kudchadkar, Ronald C. DeConti et al. · Clinical Cancer Research · 2014 · 256 citations · Full text

Medicine, Immunology, Oncology +17